# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Common variable agammaglobulinemia

Common variable immune deficiency
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 11 results.
Improving the Diagnosis of Common Variable Immune Deficiency
Status: Recruiting
Last Changed: May 17, 2019
First Received: Nov 08, 2017
Disease(s): CVI - Common Variable Immunodeficiency
Locations: UCLA, Los Angeles, California, United States
A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions
Status: Recruiting
Last Changed: Nov 19, 2019
First Received: Jul 03, 2018
Disease(s): CVI - Common Variable Immunodeficiency
Intervention(s): C1-esterase inhibitor [recombinant] (C1-INH-R)
Locations: IMMUNOe Research Centers, Centennial, Colorado, United States
Immune Regulation in Patients With Common Variable Immunodeficiency and Related Syndromes
Status: Recruiting
Last Changed: Aug 07, 2020
First Received: Nov 04, 1999
Disease(s): CVID, XLA
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study of Efficacy of CDZ173 in Patients With APDS/PASLI
Status: Recruiting
Last Changed: Apr 22, 2020
First Received: May 06, 2015
Disease(s): Common Variable Immunodeficiency (CVID) More Specifically Activated PI3Kdelta Syndrome (APDS) p110delta-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency (PASLI)
Intervention(s): CDZ173
Locations: National Institute of Health NIH, Bethesda, Maryland, United States
Novartis Investigative Site, Minsk, Belarus
Novartis Investigative Site, Prague 5, Czechia
Novartis Investigative Site, Dublin, Ireland
Novartis Investigative Site, Palermo, PA, Italy
... and 6 other locations.
Natural History of Bronchiectasis
Status: Recruiting
Last Changed: Jul 30, 2020
First Received: Jul 22, 2009
Disease(s): Bronchiectasis, Cystic Fibrosis, Autoimmune Disease, Common Variable Immunodeficiency
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Status: Recruiting
Last Changed: Apr 20, 2020
First Received: Oct 20, 2015
Disease(s): Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases, Autoimmune Lymphoproliferative, Lymphoproliferative Disorders
Intervention(s): Immunosuppression Only Conditioning - Closed with amendment L, Reduced Intensity Conditioning, Myeloablative Conditioning-Closed with amendment L, GVHD Prophylaxis, Allo BMT
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Allogeneic Hematopoietic Stem Cell Transplant for People With Primary Immunodeficiency Diseases
Status: Not yet recruiting
Last Changed: Aug 13, 2020
First Received: Apr 09, 2020
Disease(s): Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable Immunodeficiency, Primary T-cell Immunodeficiency Disorders
Intervention(s): Busulfan test dose, Fludarabine, Busulfan, Alemtuzumab, Total body Irradiation, Allogeneic HSCT, Tacrolimus (Tacro), Mycophenolate mofetil (MMF), Cyclophosphamide (Cytoxan), No intervention
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Status: Recruiting
Last Changed: Aug 04, 2020
First Received: Sep 10, 2018
Disease(s): Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders, Immune System Diseases, Common Variable Immunodeficiency
Intervention(s): Immunosuppression Only Conditioning (IOC), Reduced Intensity Conditioning (RIC), GVHD Prophylaxis, Allogeneic HSC
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland, United States
National Marrow Donor Program, Minneapolis, Minnesota, United States
Immune Disorder HSCT Protocol
Status: Recruiting
Last Changed: May 20, 2020
First Received: Apr 01, 2013
Disease(s): Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Hyper-IgM, DiGeorge Syndrome, Chediak-Higashi Syndrome, Common Variable Immune Deficiency, Immune Dysregulatory Disorders, Hemophagocytic Lymphohistiocytosis, IPEX, Autoimmune Lymphoproliferative Syndrome, X-linked Lymphoproliferative Syndrome
Intervention(s): Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
Locations: Washington University, Saint Louis, Missouri, United States
Methodist Heathcare, San Antonio, Texas, United States
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
Status: Recruiting
Last Changed: Jan 28, 2020
First Received: May 01, 2018
Disease(s): Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Acquired Neutropenia in Newborn, Acquired Anemia Hemolytic, Acquired Thrombocytopenia, Hemophagocytic Lymphohistiocytoses, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Common Variable Immunodeficiency, X-linked Lymphoproliferative Disease, Severe Combined Immunodeficiency, Hurler Syndrome, Mannosidosis, Adrenoleukodystrophy
Intervention(s): Thiotepa--single daily dose, Thiotepa--escalated dose
Locations: UF Health Shands Children's Hospital, Gainesville, Florida, United States